Clinical value of T-wave alternans assessment.
Microvolt-level T-wave alternans (TWA) is a new arrhythmia risk marker to assess subtle changes in repolarization that has been introduced for arrhythmia risk stratification. Recent experimental studies have demonstrated that it reflects a heartrate dependent increased spatial dispersion of repolarization associated with unidirectional conduction block, and reentry that may result in the occurrence of ventricular fibrillation. Clinical studies have convincingly demonstrated that TWA is closely related to arrhythmia induction in the electrophysiology (EP) laboratory as well as to the occurrence of spontaneous ventricular tachyarrhythmias in patients undergoing EP study. Subsequent studies showed that TWA-assessed noninvasively-is predictive of future arrhythmic events in patients with implanted ICDs as well as for ventricular tachyarrhythmias in patients with congestive heart failure without a prior history of arrhythmias. There is still controversy, however, about the predictive value of TWA in patients following acute myocardial infarction (MI). Several studies which differ in patient selection, pharmacologic treatment of the patients, and endpoint definitions, have reported conflicting results. Therefore, studies with a large number of unselected patients after acute MI on optimal treatment according to contemporary therapeutic guidelines as well as of patients with reduced left ventricular ejection fraction following MI are needed to define its role with regard to identifying patients who may benefit from primary preventive ICD therapy. Future research should also focus on evaluation of alternative methods to increase heart rate (i.e., pharmacological stimulation) in an attempt to reduce the proportion of incomplete tests in patients with insufficient increase in heart rate during exercise testing.
Department of Medicine, Division of Cardiology/Clinical Electrophysiology, J. W. Goethe University, Frankfurt a. M., Germany.
Thomas
T
Klingenheben
Stefan H
SH
Hohnloser
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D003936:Diagnosis, Computer-Assisted; D004562:Electrocardiography / Q000379:methods*; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology*; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000503:physiopathology*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D017180:Tachycardia, Ventricular / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology*; D016276:Ventricular Function / Q000187:drug effects / Q000502:physiology*
D000889:Anti-Arrhythmia Agents